A recent JAMA Psychiatry study found that an ADHD medicine called lisdexamfetamine reduced the risk of hospitalization due to amphetamine or methamphetamine addiciton by 18% and 14% for deaths caused by substance abuse disorders.
A recent JAMA Psychiatry study found that an ADHD medicine called lisdexamfetamine reduced the risk of hospitalization due to amphetamine or methamphetamine addiciton by 18% and 14% for deaths caused by substance abuse disorders.